



PRESS RELEASE

QUOTIENT CONSOLIDATES DRUG DEVELOPMENT BUSINESSES FOLLOWING THREE ACQUISITIONS

Businesses now fully integrated and Quotient seeking further acquisitions

Newmarket, United Kingdom, May 19, 2008 – Quotient BioResearch Limited, the leading provider of analytical and safety evaluation services and products for bioscience and sport, announces that following the recent acquisitions of HFL Limited, GR Micro Limited and BioDynamics Research Limited, it is consolidating its drug development services businesses under the name Quotient Bioresearch and renaming the parent company of the Group Quotient Bioscience Limited (“Quotient Bioscience”).

From today, therefore, HFL Limited, GR Micro Limited and BioDynamics Research Limited will all trade as Quotient Bioresearch. The sports testing and research business of HFL Limited will trade as HFL Sport Science and Alba Bioscience, the diagnostics reagents business of Quotient Bioscience, will continue to trade as Alba Bioscience.

Quotient Bioresearch provides a broad range of analytical and safety evaluation services to the pharmaceutical and biotechnology industries. With budgeted revenues of over £20 million, Quotient Bioresearch employs over 240 people in Newmarket, Rushden and London, making it one of the leading companies of its type in the UK. Customers of Quotient Bioresearch include many of the world’s leading pharmaceutical and biotechnology companies.

HFL Sport Science is a world leader in the provision of forensic quality drug surveillance services. It is also a world leader in research into the detection of banned substances.

Alba Bioscience is a world leader in the manufacture and sale of monoclonal antibody based reagents and other reagents used for blood typing and screening.

The management, operating activities, sites, and services supplied by all the companies concerned are unaffected by the changes announced today.

Paul Cowan, Chairman and Chief Executive Officer of Quotient Bioscience, said *“Since acquiring GR Micro, HFL and BioDynamics, Quotient has made excellent progress in integrating the businesses and expanding the service offering of the Group. As a result, Quotient Bioresearch has rapidly become one of Europe’s leading drug development services groups and we now wish to extend that market position through further synergistic acquisitions that build on our skillbase and expand our customer offering.”*

-ends-

Contacts:

Quotient Bioscience	Paul Cowan, Chairman and CEO	+44 (0)1638 720 500
Financial Dynamics	Ben Atwell	+44 (0)207 831 3113

Notes to editors:

Quotient Bioscience is a rapidly growing UK Group focused on the provision of high value-added analytical and safety evaluation services and products for bioscience and sport. Founded in early 2007, Quotient Bioscience has completed four acquisitions in the United Kingdom – HFL Limited in January 2007; Alba Bioscience Limited in August 2007; GR Micro Limited in September 2007; and BioDynamics Research Limited in February 2008.

Quotient Bioscience is seeking to maintain its current rate of growth through a combination of both organic growth and acquisition-led growth (both in Europe and in North America).

Our new corporate website is available at www.quotientbioscience.com.